A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,348 · see citing works

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Döhner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,686 · see citing works

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137 · see citing works

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

Slovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. P., Theil, K. S., Mohamed, A. N., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,600 · see citing works

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319 · see citing works

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961 · see citing works

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

Grimwade, D. J. (2001) · Blood · doi:10.1182/blood.v98.5.1312 · Cited by 917 · see citing works

Efficacy of Lenalidomide in Myelodysplastic Syndromes

List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., & Zeldis, J. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041668 · Cited by 880 · see citing works

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

Löwenberg, B., Ossenkoppele, G. J., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J. A., Jongen‐Lavrencic, M., von Lilienfeld‐Toal, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901409 · Cited by 828 · see citing works

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804 · see citing works

Drug therapy for acute myeloid leukemia

Tallman, M. S., Gilliland, D. G., & Rowe, J. M. (2005) · Blood · doi:10.1182/blood-2005-01-0178 · Cited by 656 · see citing works

Mechanism of action of lenalidomide in hematological malignancies

Kotla, V., Goel, S., Nischal, S., Heuck, C. J., Vivek, K., Das, B. C., & Verma, A. K. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-36 · Cited by 466 · see citing works

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia

Cashen, A. F., Schiller, G. J., O'Donnell, M. R., & DiPersio, J. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9178 · Cited by 464 · see citing works

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

Blum, W. G., Garzon, R., Klisovic, R. B., Schwind, S., Walker, A., Geyer, S. M., Liu, S., Havelange, V., Becker, H., Schaaf, L. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002650107 · Cited by 450 · see citing works

Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia

Stone, R. M., Berg, D. T., George, S. L., Dodge, R. K., Paciucci, P. A., Schulman, P., Lee, E. J., Moore, J. O., Powell, B. L., & Schiffer, C. A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322503 · Cited by 447 · see citing works

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

Raza, A., Reeves, J. A., Feldman, E. J., Dewald, G. W., Bennett, J. M., Deeg, H. J., Dreisbach, L. P., Schiffer, C. A., Stone, R. M., Greenberg, P. L., et al. (2007) · Blood · doi:10.1182/blood-2007-01-068833 · Cited by 424 · see citing works

The Outcomes and Costs of Acute Myeloid Leukemia Among the Elderly

Menzin, J., Lang, K., Earle, C. C., Kerney, D. L., & Mallick, R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.14.1597 · Cited by 276 · see citing works

Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.

Tilly, H., Castaigné, S., Bordessoule, D., Casassus, P., Prisé, P. Y. L., Tertian, G., Desablens, B., Henry-Amar, M., & Degos, L. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.2.272 · Cited by 259 · see citing works

Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients

Estey, E. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2731 · Cited by 235 · see citing works

Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study

Anderson, J. E., Kopecky, K. J., Willman, C. L., et al. (2002) · Blood · doi:10.1182/blood-2001-12-0354 · Cited by 192 · see citing works

Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors

Kantarjian, H. M., Erba, H. P., Claxton, D. F., Arellano, M. L., Lyons, R. M., Kovascovics, T. J., Gabrilove, J. L., Craig, M., Douer, D., Maris, M. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3130 · Cited by 190 · see citing works

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

Harousseau, J., Martinelli, G., Wiktor-Jędrzejczak, W., Brandwein, J. M., Bordessoule, D., Masszi, T., Ossenkoppele, G. J., Alexeeva, J. A., Beutel, G., Maertens, J. A., et al. (2009) · Blood · doi:10.1182/blood-2009-01-198093 · Cited by 149 · see citing works

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

Bartlett, J. B., Michael, A., Clarke, I., Dredge, K. S., Nicholson, S., Kristeleit, H., Polychronis, A., Pandha, H. S., Muller, G. W., Stirling, D., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601579 · Cited by 141 · see citing works

Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

Sekeres, M. A., Maciejewski, J. P., Giagounidis, A. A. N., Wride, K., Knight, R., Raza, A., & List, A. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5770 · Cited by 107 · see citing works

The Difficult Problem of Acute Myeloid Leukemia in the Older Adult

Stone, R. M. (2002) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.6.363 · Cited by 97 · see citing works

Progress in the treatment of acute myeloid leukemia

Ravandi, F., Burnett, A. K., Agura, E. D., & Kantarjian, H. M. (2007) · Cancer · doi:10.1002/cncr.23000 · Cited by 79 · see citing works

Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13

Fehniger, T. A., Byrd, J. C., Marcucci, G., Abboud, C. N., Kefauver, C. A., Payton, J. E., Vij, R., & Blum, W. G. (2008) · Blood · doi:10.1182/blood-2008-04-152678 · Cited by 76 · see citing works

Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia

Schiller, G. J., O'Brien, S. M., Pigneux, A., DeAngelo, D. J., Vey, N., Kell, J., Solomon, S. R., Stuart, R. K., Karsten, V., Cahill, A. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2008 · Cited by 74 · see citing works

General Approach to, and Perspectives on Clinical Research in, Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Estey, E. H. (2006) · Seminars in Hematology · doi:10.1053/j.seminhematol.2006.01.002 · Cited by 58 · see citing works

Treatment of acute myeloid leukemia: State-of-the-art and future directions

Stone, R. M. (2002) · Seminars in Hematology · doi:10.1053/shem.2002.35977 · Cited by 31 · see citing works

Phase II Study of High Dose Lenalidomide as Initial Treatment for Older Acute Myeloid Leukemia Patients: Early Results Show a Significant Reduction of Bone Marrow Blasts after 14 Days of Therapy.

Fehniger, T. A., Nelson, A., Trinkaus, K. M., Abboud, C. N., Cashen, A. F., DiPersio, J. F., Graubert, T. A., Ley, T. J., Tomasson, M. H., Uy, G. L., et al. (2007) · Blood · doi:10.1182/blood.v110.11.916.916 · Cited by 8 · see citing works

Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia.

Chandler, J. C., Klisovic, R. B., Phelps, M. A., et al. (2009) · Blood · doi:10.1182/blood.v114.22.841.841 · Cited by 2 · see citing works

Preliminary results of a phase II study of high dose lenalidomide as initial therapy for acute myeloid leukemia in patients ≥ 60 years old

Fehniger, T. A., Nelson, A., Trinkaus, K., Abboud, C. N., Cashen, A. F., DiPersio, J. F., Ley, T. J., Uy, G. L., Westervelt, P., & Vij, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.7058 · Cited by 1 · see citing works

Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide

Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137 · see citing works

Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice

Fink, E. C., McConkey, M., Adams, D. N., Haldar, S. D., Kennedy, J. A., Guirguis, A. A., Udeshi, N. D., Mani, D. R., Chen, M., Liddicoat, B., et al. (2018) · Blood · doi:10.1182/blood-2018-05-852798 · Cited by 131 · see citing works

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605

Sekeres, M. A., Gundacker, H., Lancet, J., Advani, A., Petersdorf, S., Liesveld, J., Mulford, D., Norwood, T., Willman, C. L., Appelbaum, F. R., et al. (2011) · Blood · doi:10.1182/blood-2011-02-337303 · Cited by 80 · see citing works

The application and biology of immunomodulatory drugs (IMiDs) in cancer

Pan, B., & Lentzsch, S. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.004 · Cited by 76 · see citing works

Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia

Craddock, C., Slade, D., De Santo, C., Wheat, R., Ferguson, P., Hodgkinson, A., Brock, K., Cavenagh, J., Ingram, W., Dennis, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00889 · Cited by 73 · see citing works

A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia

DeAngelo, D. J., Brunner, A. M., Werner, L., Avigan, D., Fathi, A. T., Sperling, A. S., Washington, A., Stroopinsky, D., Rosenblatt, J., McMasters, M., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.24968 · Cited by 16 · see citing works

Novel insights into the mechanism of action of lenalidomide

Semeraro, M., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.28386 · Cited by 19 · see citing works

Cyclosporine Broadens the Therapeutic Potential of Lenalidomide in Myeloid Malignancies

Dou, A., & Fang, J. (2020) · Journal of Cellular Immunology · doi:10.33696/immunology.2.049 · Cited by 5 · see citing works

Lenalidomide-induced severe hepatotoxicity

Hussain, S., Browne, R., Chen, J. Y., et al. (2007) · Blood · doi:10.1182/blood-2007-06-097758 · Cited by 32 · see citing works

Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide

Bartlett, J. B., Tozer, A., Stirling, D., & Zeldis, J. B. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602774 · Cited by 70 · see citing works

Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database

Olivier, P., Teisseyre, A.-C., & Montastruc, J. (2013) · Medical Oncology · doi:10.1007/s12032-013-0733-2 · Cited by 7 · see citing works